Patent SG-11201903336U-A (SG)
Title: Inhibitor of rna polymerase ii
Inventor: SVANBORG CATHARINA
IPC: G01N33/50
Filed: 2017-10-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/073725 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 35/74 (2015.01) A61P 13/02 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 38/16 (2006.01) GO1N 33/50 (2006.01) A61P 13/00 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/1B2017/056413 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 16 October 2017 (16.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617548.1 17 October 2016 (17.10.2016) GB (71) Applicant: LINNANE PHARMA AB [SE/SE]; Slotts- gatan 32, 21133 Malmo (SE). (72) Inventors: SVANBORG, Catharina; Slottsgatan 32, 21133 Malmo (SE). FILENKO, Nina; Department of Mi- crobiology, Immunology and Glycobiology (MIG), Insti- tute of Laboratory Medicine, Lund University, Solvegatan 23, 223 62 Lund (SE). AMBITE, Ines; Department of Mi- crobiology, Immunology and Glycobiology (MIG), Insti- tute of Laboratory Medicine, Lund University, Solvegaten 23, 223 62 Lund (SE). Agent: GREAVES, Carol; C.P.Greaves & Co, 80 Church (74) Road, Winscombe Somerset BS25 1BP (GB). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (84) 1-1 in ei IN (54) Title: INHIBITOR OF RNA POLYMERASE II en I N (57) : An inhibitor of RNA polymerase II is described, wherein said inhibitor is selected a moiety which targets a protein 0 ----. selected from cyclin kinase 12 (CDK12) or its recruiting protein PAF1C. Particular examples of such inhibitors are polypeptides ex- GC ,_ 1 pressed by a gene selected from IldD, IldR, nlpD or rfaH of a bacterial species, such as a commensal bacteria or asymptomatic carrier, © or a variant of said protein. Inhibitors may be based upon bacterial Sigma S or Np1D proteins. These inhibitors are useful in therapies, N to suppress protein expression. Thus they may be used as immunosuppressants, anti-inflammatory or anti- infection agents. C